$92.56 1.4%
LNTH Stock Price vs. AI Score
Data gathered: December 26

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - Lantheus (LNTH)

Analysis generated November 15, 2024. Powered by Chat GPT.

Lantheus Holdings, Inc. is a prominent player in the healthcare sector, primarily specializing in diagnostic imaging agents and products. The company provides medical imaging solutions that help healthcare professionals diagnose and treat diseases more effectively. Lantheus’ portfolio includes nuclear imaging, ultrasound contrast agents, and other imaging products. Given its critical role in the healthcare diagnostics market, Lantheus is well-positioned to benefit from the ongoing advancements in medical technologies.

Read full AI stock Analysis

Stock Alerts - Lantheus (LNTH)

company logo Lantheus | December 15
Reddit mentions are up by 765% in the last 24h.
company logo Lantheus | November 20
AI Score is up by 26% in the last couple of days.
company logo Lantheus | November 20
Price is up by 5.9% in the last 24h.
company logo Lantheus | November 20
Insider Alert: Marshall Robert J. Jr. is selling shares

About Lantheus

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.


Lantheus
Price $92.56
Target Price Sign up
Volume 43,030
Market Cap $6.35B
Year Range $63.07 - $123.62
Dividend Yield 0%
PE Ratio 15.17
Analyst Rating 100% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q3 '24379M233M242M131M189M1.700
Q2 '24394M241M256M62M92M1.800
Q1 '24365M232M242M131M186M1.690
Q4 '23349M237M230M103M181M1.750
Q3 '23315M196M200M132M168M1.470

Insider Transactions View All

Marshall Robert J. Jr. filed to sell 102,963 shares at $81.2.
November 19 '24
Blanchfield Paul filed to sell 97,092 shares at $79.7.
November 18 '24
Thrall James H filed to sell 34,207 shares at $98.5.
August 23 '24
Niedzwiecki Daniel filed to sell 77,744 shares at $97.5.
August 16 '24
Ber Gerard filed to sell 21,221 shares at $97.8.
August 14 '24

What is the Market Cap of Lantheus?

The Market Cap of Lantheus is $6.35B.

What is Lantheus' PE Ratio?

As of today, Lantheus' PE (Price to Earnings) ratio is 15.17.

What is the current stock price of Lantheus?

Currently, the price of one share of Lantheus stock is $92.56.

How can I analyze the LNTH stock price chart for investment decisions?

The LNTH stock price chart above provides a comprehensive visual representation of Lantheus' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Lantheus shares. Our platform offers an up-to-date LNTH stock price chart, along with technical data analysis and alternative data insights.

Does LNTH offer dividends to its shareholders?

As of our latest update, Lantheus (LNTH) does not offer dividends to its shareholders. Investors interested in Lantheus should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Lantheus?

Some of the similar stocks of Lantheus are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.